These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 12054061)

  • 21. [A new approach to antischizophrenic therapeutics: D2 dopamine receptor partial agonists].
    Costentin J
    Ann Pharm Fr; 2009 Sep; 67(5):310-9. PubMed ID: 19695367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
    Stip E; Tourjman V
    Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dopamine receptor downregulation: an alternative strategy for schizophrenia treatment.
    Tsai SJ
    Med Hypotheses; 2004; 63(6):1047-50. PubMed ID: 15504573
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of aripiprazole and quinagolide, a dopamine agonist, in a patient with symptomatic pituitary prolactinoma and chronic psychosis.
    Broekhof R; Gosselink MJ; Pijl H; Giltay EJ
    Gen Hosp Psychiatry; 2012; 34(2):209.e1-3. PubMed ID: 21872335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism.
    Naber D; Lambert M
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Dec; 28(8):1213-9. PubMed ID: 15588748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912.
    Tadori Y; Kitagawa H; Forbes RA; McQuade RD; Stark A; Kikuchi T
    Eur J Pharmacol; 2007 Nov; 574(2-3):103-11. PubMed ID: 17692841
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
    Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
    Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity.
    Kikuchi T; Tottori K; Uwahodo Y; Hirose T; Miwa T; Oshiro Y; Morita S
    J Pharmacol Exp Ther; 1995 Jul; 274(1):329-36. PubMed ID: 7616416
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Agitation associated with aripiprazole initiation.
    Lea JW; Stoner SC; Lafollette J
    Pharmacotherapy; 2007 Sep; 27(9):1339-42. PubMed ID: 17723088
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aripiprazole: does partial dopaminergic agonism translate into clinical benefits?
    Crismon ML; DeLeon A; Miller AL
    Ann Pharmacother; 2003 May; 37(5):738-40. PubMed ID: 12708954
    [No Abstract]   [Full Text] [Related]  

  • 31. Dopamine D2(High) receptors moderately elevated by bifeprunox and aripiprazole.
    Seeman P
    Synapse; 2008 Dec; 62(12):902-8. PubMed ID: 18792990
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice.
    Leite JV; Guimarães FS; Moreira FA
    Eur J Pharmacol; 2008 Jan; 578(2-3):222-7. PubMed ID: 18021764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aripiprazole: profile on efficacy and safety.
    Goodnick PJ; Jerry JM
    Expert Opin Pharmacother; 2002 Dec; 3(12):1773-81. PubMed ID: 12472374
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology.
    Davies MA; Sheffler DJ; Roth BL
    CNS Drug Rev; 2004; 10(4):317-36. PubMed ID: 15592581
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical impact of aripiprazole in patients suffering from schizophrenia].
    Levoyer D; Drapier D; Fadier-Salicé G; Millet B
    Encephale; 2007; 33(3 Pt 1):332-8. PubMed ID: 17675931
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives.
    Oshiro Y; Sato S; Kurahashi N; Tanaka T; Kikuchi T; Tottori K; Uwahodo Y; Nishi T
    J Med Chem; 1998 Feb; 41(5):658-67. PubMed ID: 9513593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antipsychotic drug action: antagonism, inverse agonism or partial agonism.
    Strange PG
    Trends Pharmacol Sci; 2008 Jun; 29(6):314-21. PubMed ID: 18471899
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined use of ECT with aripiprazole.
    Lopez-Garcia P; Chiclana C; Gonzalez R
    World J Biol Psychiatry; 2009; 10(4 Pt 3):942-3. PubMed ID: 17853257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release.
    Aihara K; Shimada J; Miwa T; Tottori K; Burris KD; Yocca FD; Horie M; Kikuchi T
    Brain Res; 2004 Apr; 1003(1-2):9-17. PubMed ID: 15019558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling.
    Jordan S; Regardie K; Johnson JL; Chen R; Kambayashi J; McQuade R; Kitagawa H; Tadori Y; Kikuchi T
    J Psychopharmacol; 2007 Aug; 21(6):620-7. PubMed ID: 17092971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.